Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response

Susan N. Thomas, Efthymia Vokali, Amanda Lund, Jeffrey A. Hubbell, Melody A. Swartz

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Accumulating evidence implicates the tumor-draining lymph node (TDLN) in tumor-induced immune escape, as it drains regulatory molecules and leukocytes from the tumor microenvironment. We asked whether targeted delivery of adjuvant to the TDLN, presumably already bathed in tumor antigens, could promote anti-tumor immunity and hinder tumor growth. To this end, we used 30nm polymeric nanoparticles (NPs) that effectively target dendritic cells (DCs, CD11c+) within the lymph node (LN) after intradermal administration. These NPs accumulated within the TDLN when administered in the limb ipsilateral (i.l.) to the tumor or in the non-TDLN when administered in the contralateral (c.l.) limb. Incorporating the adjuvants CpG or paclitaxel into the NPs (CpG-NP and PXL-NP) induced DC maturation invitro. When administered daily i.l. and thus targeting the TDLN of a B16-F10 melanoma, adjuvanted NPs induced DC maturation within the TDLN and reshaped the CD4+ T cell distribution within the tumor towards a Th1 (CXCR3+) phenotype. Importantly, this also led to an increase in the frequency of antigen-specific CD8+ T cells within the tumor. This correlated with slowed tumor growth, in contrast to unhindered tumor growth after c.l. delivery of adjuvanted NPs (targeting a non-TDLN) or i.l. delivery of free adjuvant. CpG-NP treatment in the i.l. limb also was associated with an increase in CD8+/CD4+ T cell ratios and frequencies of activated (CD25+) CD8+ T cells within the TDLN whereas PXL-NP treatment reduced the frequency of regulatory T (FoxP3+ CD4+) cells in the TDLN. Together, these data implicate the TDLN as a delivery target for adjuvant therapy of solid tumors.

Original languageEnglish (US)
Pages (from-to)814-824
Number of pages11
JournalBiomaterials
Volume35
Issue number2
DOIs
StatePublished - Jan 2014
Externally publishedYes

Fingerprint

Nanoparticles
Tumors
Lymph Nodes
Neoplasms
T-cells
T-Lymphocytes
Extremities
Antigens
Growth
Tumor Escape
CD8 Antigens
Experimental Melanomas
Tumor Microenvironment
Neoplasm Antigens
Paclitaxel
Dendritic Cells
Immunity
Leukocytes

Keywords

  • Drug delivery
  • Immunomodulation
  • Immunotherapy
  • Sentinel lymph node
  • Tumor-draining lymph node

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. / Thomas, Susan N.; Vokali, Efthymia; Lund, Amanda; Hubbell, Jeffrey A.; Swartz, Melody A.

In: Biomaterials, Vol. 35, No. 2, 01.2014, p. 814-824.

Research output: Contribution to journalArticle

Thomas, Susan N. ; Vokali, Efthymia ; Lund, Amanda ; Hubbell, Jeffrey A. ; Swartz, Melody A. / Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. In: Biomaterials. 2014 ; Vol. 35, No. 2. pp. 814-824.
@article{89e680e38bda410fbe510f2aaf3448d4,
title = "Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response",
abstract = "Accumulating evidence implicates the tumor-draining lymph node (TDLN) in tumor-induced immune escape, as it drains regulatory molecules and leukocytes from the tumor microenvironment. We asked whether targeted delivery of adjuvant to the TDLN, presumably already bathed in tumor antigens, could promote anti-tumor immunity and hinder tumor growth. To this end, we used 30nm polymeric nanoparticles (NPs) that effectively target dendritic cells (DCs, CD11c+) within the lymph node (LN) after intradermal administration. These NPs accumulated within the TDLN when administered in the limb ipsilateral (i.l.) to the tumor or in the non-TDLN when administered in the contralateral (c.l.) limb. Incorporating the adjuvants CpG or paclitaxel into the NPs (CpG-NP and PXL-NP) induced DC maturation invitro. When administered daily i.l. and thus targeting the TDLN of a B16-F10 melanoma, adjuvanted NPs induced DC maturation within the TDLN and reshaped the CD4+ T cell distribution within the tumor towards a Th1 (CXCR3+) phenotype. Importantly, this also led to an increase in the frequency of antigen-specific CD8+ T cells within the tumor. This correlated with slowed tumor growth, in contrast to unhindered tumor growth after c.l. delivery of adjuvanted NPs (targeting a non-TDLN) or i.l. delivery of free adjuvant. CpG-NP treatment in the i.l. limb also was associated with an increase in CD8+/CD4+ T cell ratios and frequencies of activated (CD25+) CD8+ T cells within the TDLN whereas PXL-NP treatment reduced the frequency of regulatory T (FoxP3+ CD4+) cells in the TDLN. Together, these data implicate the TDLN as a delivery target for adjuvant therapy of solid tumors.",
keywords = "Drug delivery, Immunomodulation, Immunotherapy, Sentinel lymph node, Tumor-draining lymph node",
author = "Thomas, {Susan N.} and Efthymia Vokali and Amanda Lund and Hubbell, {Jeffrey A.} and Swartz, {Melody A.}",
year = "2014",
month = "1",
doi = "10.1016/j.biomaterials.2013.10.003",
language = "English (US)",
volume = "35",
pages = "814--824",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response

AU - Thomas, Susan N.

AU - Vokali, Efthymia

AU - Lund, Amanda

AU - Hubbell, Jeffrey A.

AU - Swartz, Melody A.

PY - 2014/1

Y1 - 2014/1

N2 - Accumulating evidence implicates the tumor-draining lymph node (TDLN) in tumor-induced immune escape, as it drains regulatory molecules and leukocytes from the tumor microenvironment. We asked whether targeted delivery of adjuvant to the TDLN, presumably already bathed in tumor antigens, could promote anti-tumor immunity and hinder tumor growth. To this end, we used 30nm polymeric nanoparticles (NPs) that effectively target dendritic cells (DCs, CD11c+) within the lymph node (LN) after intradermal administration. These NPs accumulated within the TDLN when administered in the limb ipsilateral (i.l.) to the tumor or in the non-TDLN when administered in the contralateral (c.l.) limb. Incorporating the adjuvants CpG or paclitaxel into the NPs (CpG-NP and PXL-NP) induced DC maturation invitro. When administered daily i.l. and thus targeting the TDLN of a B16-F10 melanoma, adjuvanted NPs induced DC maturation within the TDLN and reshaped the CD4+ T cell distribution within the tumor towards a Th1 (CXCR3+) phenotype. Importantly, this also led to an increase in the frequency of antigen-specific CD8+ T cells within the tumor. This correlated with slowed tumor growth, in contrast to unhindered tumor growth after c.l. delivery of adjuvanted NPs (targeting a non-TDLN) or i.l. delivery of free adjuvant. CpG-NP treatment in the i.l. limb also was associated with an increase in CD8+/CD4+ T cell ratios and frequencies of activated (CD25+) CD8+ T cells within the TDLN whereas PXL-NP treatment reduced the frequency of regulatory T (FoxP3+ CD4+) cells in the TDLN. Together, these data implicate the TDLN as a delivery target for adjuvant therapy of solid tumors.

AB - Accumulating evidence implicates the tumor-draining lymph node (TDLN) in tumor-induced immune escape, as it drains regulatory molecules and leukocytes from the tumor microenvironment. We asked whether targeted delivery of adjuvant to the TDLN, presumably already bathed in tumor antigens, could promote anti-tumor immunity and hinder tumor growth. To this end, we used 30nm polymeric nanoparticles (NPs) that effectively target dendritic cells (DCs, CD11c+) within the lymph node (LN) after intradermal administration. These NPs accumulated within the TDLN when administered in the limb ipsilateral (i.l.) to the tumor or in the non-TDLN when administered in the contralateral (c.l.) limb. Incorporating the adjuvants CpG or paclitaxel into the NPs (CpG-NP and PXL-NP) induced DC maturation invitro. When administered daily i.l. and thus targeting the TDLN of a B16-F10 melanoma, adjuvanted NPs induced DC maturation within the TDLN and reshaped the CD4+ T cell distribution within the tumor towards a Th1 (CXCR3+) phenotype. Importantly, this also led to an increase in the frequency of antigen-specific CD8+ T cells within the tumor. This correlated with slowed tumor growth, in contrast to unhindered tumor growth after c.l. delivery of adjuvanted NPs (targeting a non-TDLN) or i.l. delivery of free adjuvant. CpG-NP treatment in the i.l. limb also was associated with an increase in CD8+/CD4+ T cell ratios and frequencies of activated (CD25+) CD8+ T cells within the TDLN whereas PXL-NP treatment reduced the frequency of regulatory T (FoxP3+ CD4+) cells in the TDLN. Together, these data implicate the TDLN as a delivery target for adjuvant therapy of solid tumors.

KW - Drug delivery

KW - Immunomodulation

KW - Immunotherapy

KW - Sentinel lymph node

KW - Tumor-draining lymph node

UR - http://www.scopus.com/inward/record.url?scp=84886749794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886749794&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.10.003

DO - 10.1016/j.biomaterials.2013.10.003

M3 - Article

VL - 35

SP - 814

EP - 824

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 2

ER -